<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282538</url>
  </required_header>
  <id_info>
    <org_study_id>17411953800</org_study_id>
    <nct_id>NCT04282538</nct_id>
  </id_info>
  <brief_title>Efficacy of rTMS and tDCS as Adjunctive Rehabilitation for Cerebrovascular Disease-related Gait Dysfunction</brief_title>
  <official_title>Efficacy of Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation as Adjunctive Rehabilitation for Cerebrovascular Disease-related Gait Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>zsneurology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a prospective, randomized, single-blind, parallel-controlled, multicenter
      clinical study to evaluate the efficacy and safety of repetitive transcranial magnetic
      stimulation and transcranial direct current stimulation assisted rehabilitation in the
      treatment of cerebrovascular disease-related gait disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a prospective, randomized, single-blind, parallel-controlled, multicenter
      clinical study. The main purpose was to evaluate the efficacy and safety of repetitive
      transcranial magnetic stimulation and transcranial direct current stimulation assisted
      rehabilitation in the treatment of cerebrovascular disease-related gait disorders. The
      secondary objective was to assess the effects of these two types of neuromodulation on
      cognitive, emotional, and daily living abilities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Velocity of 10m walking test</measure>
    <time_frame>12 weeks</time_frame>
    <description>Velocity of 10m walking test (10MWT) according to the video</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10m walking test</measure>
    <time_frame>12 weeks</time_frame>
    <description>Step width, step size, step frequency of 10m walking test (10MWT) according to the video</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Turn time of time up and go test</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total time, pace, standing time, turn time of time up and go test (TUGT) according to the video</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual-task walking</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pace, step width, step size, step frequency, dual task cost of dual-task walking (DTW) according to the video</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tinetti Balance and Gait Analysis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gait evaluation according to Tinetti Balance and Gait Analysis (Full score: 28. score &gt;= 19 indicates high risk of fall.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-mental state examination (MMSE)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cognition evaluation according to Mini-mental state examination (Full score: 30. score &lt;24 indicates cognitive impairment. )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal cognitive assessment (MoCA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cognition evaluation according to Montreal cognitive assessment (Full score: 30. score &lt;26 indicates cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol digit modalities test (SDMT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Attention evaluation according to Symbol digit modalities test (Counting number of right modalities in 90s. )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color word test (CWT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Execution evaluation according to Color word test (Counting number of right ones. )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton depression scale (HAMD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mood evaluation according to Hamilton depression scale (Score &gt;7 indicates possible depression.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental activities of daily living (IADL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Daily living ability evaluation according to Instrumental activities of daily living (Full score: 24. Higher score indicates higher independence. )</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Repetitive Transcranial Magnetic Stimulation</condition>
  <condition>Transcranial Direct Current Stimulation</condition>
  <condition>Cerebrovascular Disease</condition>
  <condition>Gait Dysfunction, Neurologic</condition>
  <arm_group>
    <arm_group_label>Group A - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active rTMS for Gait Dysfunction of Hemiplegia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A - Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham rTMS for Gait Dysfunction of Hemiplegia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active tDCS for Frontal Gait Dysfunction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tDCS for Frontal Gait Dysfunction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active rTMS</intervention_name>
    <description>4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)</description>
    <arm_group_label>Group A - Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>4-week (5 days per week) sham rTMS</description>
    <arm_group_label>Group A - Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)</description>
    <arm_group_label>Group B - Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>4-week (5 days per week) sham tDCS</description>
    <arm_group_label>Group B - Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Walking training</intervention_name>
    <description>4-week (5 days per week) walking training</description>
    <arm_group_label>Group A - Active</arm_group_label>
    <arm_group_label>Group A - Sham</arm_group_label>
    <arm_group_label>Group B - Active</arm_group_label>
    <arm_group_label>Group B - Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognition training</intervention_name>
    <description>4-week (5 days per week) cognition training</description>
    <arm_group_label>Group B - Active</arm_group_label>
    <arm_group_label>Group B - Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Group A: Gait Dysfunction of Hemiplegia

               -  Age ≥ 35 years old, ≤ 75 years old;

               -  There was a cerebral infarction event in the past ≥ 2 months, leaving unilateral
                  lower extremity paralysis, muscle strength IV to V- grade;

               -  Brunnstrom staging: lower limb of paralysis (IV-V grade), lower limb of healthy
                  side (IV-V grade), upper limbs (IV-V grade), hands (IV-V grade);

               -  Able to stand for 5 minutes without assistance, without gait aid, and to walk
                  independently for 5 minutes without stopping;

               -  Mini-mental state examination (MMSE) &gt; 17 points, able to complete cognitive and
                  gait assessments.

          2. Group B: Frontal Gait Dysfunction

               -  Age ≥ 35 years old, ≤ 75 years old;

               -  Meet the frontal gait characteristics: a) Balance dysfunction: wide step base,
                  trunk swing, increased fall, decreased trunk movement control, and autonomous
                  activity dysfunction; b) difficulty in starting, dragging and freezing; c)
                  without limb ataxia, dysarthria, nystagmus, decreased facial expression,
                  decreased upper limb joint activity, upper motor neuron impaired signs, and
                  resting tremor;

               -  There was a cerebral infarction event ≥ 2 months, or asymptomatic stroke event
                  but the head MRI suggested single or multiple lacunar infarction or ischemic
                  lesion (diameter ≤ 2cm);

               -  limb muscle strength V- to V grade, and the muscle strength of both limbs is the
                  same;

               -  Able to stand for 5 minutes without assistance, without gait aid, to walk
                  independently for 5 minutes;

               -  Able to complete cognitive and gait assessments.

        Exclusion Criteria:

          -  Other gait abnormalities caused by other diseases, such as Parkinson's disease,
             hydrocephalus, cerebellar disease, vestibular system disease, extrapyramidal
             abnormalities, abnormalities of proprioceptive sensibility, visual abnormalities,
             auditory abnormalities, peripheral nerves and musculoskeletal diseases;

          -  Symptomatic cerebral infarction &lt;2 months; Severe nervous system diseases, such as
             previous cerebral hemorrhage, history of subarachnoid hemorrhage, craniocerebral
             trauma, cerebral vascular malformation, brain tumor, central nervous system infection,
             demyelinating disease, epilepsy, myelopathy, etc.;

          -  Severe cognitive impairment, major depression, and aphasia disable to finish the
             cognitive and gait assessments;

          -  serious cardiovascular, pulmonary, blood, rheumatism and other complications,
             pregnancy;

          -  Metal implants such as pacemakers or cochlear implants;

          -  Taking drugs that affect cortical excitability: such as antiepileptic drugs, sedation,
             benzodiazepines, antidepressants, dopamine, amphetamines, etc.;

          -  long-term heavy drinking: the alcohol content of men drinking more than 168g per week,
             women more than 112g;

          -  Neurological rehabilitation treatment was received within 1 month before the start of
             the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Wang, MD</last_name>
    <phone>02164041991</phone>
    <email>wang.xin@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Ding, MD</last_name>
    <phone>02164041991</phone>
    <email>ding.jing@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XIn Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Eighth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Shen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Huadong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JieJiao Zheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YuWu Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueyuan Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Xuhui District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Yang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>zsneurology</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

